Why Heparin is Given IV Before Coronary Angiography
Intravenous unfractionated heparin (UFH) is administered before coronary angiography to prevent acute thrombotic complications—specifically clot formation on coronary guidewires, catheters, and at sites of arterial injury during the procedure. 1
Primary Mechanism and Rationale
UFH serves as essential intraprocedural anticoagulation by:
- Preventing catheter-related thrombosis: The mechanical instrumentation of coronary vessels with guidewires and catheters creates a highly thrombogenic environment 1
- Protecting against arterial injury: Vascular access and catheter manipulation cause endothelial disruption, triggering the coagulation cascade 1
- Reducing acute ischemic complications: In unstable angina/NSTEMI patients, preprocedural heparin significantly decreases abrupt vessel closure (1.5% vs 8.3% without heparin, p<0.01) and improves procedural success rates (91% vs 81%, p=0.02) 2
Evidence-Based Dosing Strategy
For diagnostic angiography proceeding to PCI:
- 70-100 U/kg IV bolus when no GP IIb/IIIa inhibitor is planned 3
- 50-60 U/kg IV bolus if GP IIb/IIIa inhibitors will be used 3
The 2011 ACCF/AHA/SCAI guidelines provide Class I recommendations for UFH use during PCI, with weight-based dosing preferred over fixed dosing to avoid "overshooting" ACT values and minimize bleeding risk 1.
Monitoring Requirements
Target activated clotting time (ACT):
- 250-300 seconds is the therapeutic goal 1
- ACT monitoring is superior to aPTT during procedures because higher anticoagulation levels are needed than aPTT can discriminate 1
- Very high ACT values (>400-600 seconds) increase bleeding complications 1
Important caveat: Recent data shows significant variability in heparin response—only 49% of patients achieve target ACT with the recommended initial bolus dose (70-100 U/kg), and obese patients require lower weight-adjusted doses 4. This underscores the importance of ACT-guided dosing adjustments.
Clinical Context Matters
For UA/NSTEMI patients:
- Continue UFH if already initiated before angiography (Level of Evidence: B) 5
- Prolonged preprocedural heparin (≥24 hours) in unstable angina reduces thrombotic vessel occlusion from 12.4% to 1.5% (p<0.001) 2
For STEMI patients undergoing primary PCI:
- Recent evidence (HELP-PCI trial, 2025) demonstrates that pre-treatment with UFH 100 U/kg at first medical contact improves spontaneous reperfusion (TFG-3: 23.6% vs 17.6%, p=0.02) without increasing bleeding risk 6
Post-Procedure Management
Discontinue anticoagulation after uncomplicated diagnostic angiography or PCI (Level of Evidence: B) 5. Routine post-procedural heparin infusion is no longer recommended and may increase bleeding, particularly with concurrent GP IIb/IIIa inhibitors 1.
Alternative Anticoagulants
While UFH remains the most widely used anticoagulant (80% of US practice), alternatives include:
- Bivalirudin: Class I recommendation as alternative to UFH 7
- Enoxaparin: Class IIa as reasonable alternative in UA/NSTEMI 1
- Critical warning: Do NOT give UFH to patients already receiving therapeutic enoxaparin—this increases bleeding without benefit (Class III: Harm) 7
Key Pitfalls to Avoid
- Medication errors: Confirm correct vial strength—do NOT confuse with catheter lock flush vials 8
- Crossover anticoagulation: Switching between anticoagulants (e.g., adding UFH to enoxaparin) significantly increases bleeding risk 1
- Fixed dosing: Weight-based dosing is superior to fixed dosing, particularly in obese patients who require lower U/kg doses 4
- HIT risk: Monitor platelet counts throughout therapy; heparin-induced thrombocytopenia occurred in 13.1% of patients in HORIZONS trial 9